BTG GETS EXCLUSIVE LICENSE TO NEW CLASS OF CANCER DRUG.BTG BTG BIT (Built-In Test) Target Generator BTG Bridging the Gap BTG British Technology Group BtG Betreuungsgesetz (Germany) BTG Biomass Technology Group BV BTG Begbies Traynor Group (LSE LSE - Language Sensitive Editor : BGC BGC General Cable Corporation (stock symbol) BGC Billy Graham Center BGC Baptist General Conference (formerly Swedish Baptist Denomination) BGC Boys & Girls Club BGC Bubblegum Crisis ),West Conshohocken, Pa., the intellectual property and technology commercialization company, has concluded a license and research collaboration agreement with Cancer Research Technology Limited (CRT (1) (C RunTime) See runtime library. (2) (Cathode Ray Tube) A vacuum tube used as a display screen in a computer monitor or TV. The viewing end of the tube is coated with phosphors, which emit light when struck by electrons. ), the technology transfer company of the charity Cancer Research UK, and The Institute of Cancer Research, for a new class of cancer drug. Under the terms of this agreement (financial details were not disclosed), BTG has obtained exclusive worldwide rights to a series of novel quinazoline anti-tumor agents developed by Professor Ann Jackman and colleagues at The Institute of Cancer Research. These patented compounds are potent tumor growth inhibitors and appear to have a unique mechanism of action. Given their very promising anti-tumor activity in xenograft xenograft /xeno·graft/ (zen´o-graft) a graft of tissue transplanted between animals of different species; it may be concordant, models, they show early signs of being an exciting novel class of anti-tumor agent. BTG will be responsible for the future development and commercialization of these compounds, in the first instance partly through a sponsored collaboration at The Institute of Cancer Research. Within this collaborative program, Professor Jackman and colleagues will continue their laboratory studies on the compounds. BTG intends to then carry the work forward towards entry into the clinic. Harpal Kumar, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CRT, commented, "CRT is pleased to have entered into this partnership with BTG and The Institute of Cancer Research. We look forward to seeing these promising therapeutic agents progress towards the clinic, with the long-term aim of achieving patient benefit." Roger Harrison, head of BTG's Oncology Business Unit, said, "The laboratory data on these compounds is impressive and suggests an exciting new mode of action. Given confirmation of these data, our aim will be to seek early proof-of-concept before licensing on to a pharmaceutical company partner. This is the model we are using successfully for our other cancer drugs, BGC 9331 and BGC 945." About BTG BTG creates value by investing in intellectual property and technology development, and in early stage ventures. We realize value through technology licensing, patent assertion and disposal of equity investments. Through a multi-disciplinary approach, we apply intellectual property and commercial expertise, together with specialist skills in science and technology, to create major product opportunities in the health and high tech sectors. BTG has commercialized important innovations, including alemtuzumab (Campathr), the first monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing treatment for chronic lymphocytic lymphocytic pertaining to, characterized by or of the nature of lymphocytes. See also lymphocytic-plasmacytic. lymphocytic choriomeningitis (LCM) leukaemia and Factor IX blood clotting blood clotting, process by which the blood coagulates to form solid masses, or clots. In minor injuries, small oval bodies called platelets, or thrombocytes, tend to collect and form plugs in blood vessel openings. protein, the first recombinant treatment for Hemophilia B hemophilia B n. A clotting disorder of blood resembling hemophilia A, caused by hereditary deficiency of factor IX. Also called Christmas disease. . BTG operates through wholly owned subsidiaries Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. BTG international Ltd. and BTG international Inc. in the UK and USA, respectively. Further information about BTG can be found at http://www.btgplc.com. About The Institute of Cancer Research The Institute of Cancer Research is one of the world's leading cancer research organizations and is internationally renowned for the quality of its science. The Institute was founded in 1909 to investigate the causes of cancer and develop new strategies for its prevention, diagnosis, treatment and cure. Its mission is the relief of human suffering by pursuing excellence in the fight against cancer. The Institute is a College of the University of London For most practical purposes, ranging from admission of students to negotiating funding from the government, the 19 constituent colleges are treated as individual universities. Within the university federation they are known as Recognised Bodies and works in a unique partnership with The Royal Marsden Hospital. Together they form Europe's largest comprehensive cancer center. The Institute is a charity that relies on voluntary income. Further information about The Institute of Cancer Research can be found at http://www.icr.ac.uk. About Cancer Research Technology Limited Cancer Research Technology Limited (CRT) is a specialist technology transfer company which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. Further information about CRT can be found at http://www.cancertechnology.co.uk. About Cancer Research UK Cancer Research UK is Europe's leading cancer charity, dedicated to research into the causes, prevention and treatment of cancer. It supports the work of 3,000 scientists, doctors and nurses in over 80 academic centers across the UK. Cancer Research UK is the European leader in the development of novel anti-cancer treatments, from their discovery at the laboratory bench to early clinical trials in cancer patients. Further information about Cancer Research UK can be found at http://www.cancerresearchuk.org. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion